Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea · Delayed Price · Currency is KRW 1,710,000
-9,000 (-0.52%)
At close: Feb 13, 2026
Samsung Biologics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 1,083,316 | 857,691 | 798,056 | 393,589 |
Depreciation & Amortization | 599,101 | 489,782 | 308,264 | 161,789 |
Loss (Gain) From Sale of Assets | 2,199 | 3,866 | 2,588 | 7,466 |
Asset Writedown & Restructuring Costs | 62,655 | - | - | 725.89 |
Loss (Gain) From Sale of Investments | -597.28 | -5,152 | -72,653 | -269.12 |
Loss (Gain) on Equity Investments | -2,660 | 499.42 | -27,260 | -13,853 |
Provision & Write-off of Bad Debts | -6,380 | 21,511 | 22,407 | 4,857 |
Other Operating Activities | -33,004 | -711.89 | 185,130 | 135,132 |
Change in Accounts Receivable | -450,992 | 30,127 | -305,336 | -120,660 |
Change in Inventory | -236,200 | -273,896 | -179,912 | -370,571 |
Change in Accounts Payable | 409,295 | 267,037 | 134,594 | 21,060 |
Change in Unearned Revenue | 10.58 | 27,199 | 44,017 | - |
Change in Other Net Operating Assets | 232,511 | 248,276 | 43,151 | 235,330 |
Operating Cash Flow | 1,659,255 | 1,666,229 | 953,048 | 454,596 |
Operating Cash Flow Growth | -0.42% | 74.83% | 109.65% | 124.95% |
Capital Expenditures | -1,303,573 | -995,071 | -956,840 | -406,254 |
Sale of Property, Plant & Equipment | 1,389 | 2,811 | 64.01 | 37.64 |
Cash Acquisitions | -601,956 | -1,071,525 | -1,081,821 | - |
Sale (Purchase) of Intangibles | -73,952 | -110,254 | -52,386 | -14,898 |
Investment in Securities | 734,318 | 607,760 | -1,015,673 | -512,375 |
Other Investing Activities | -0 | -0 | 178.52 | -0 |
Investing Cash Flow | -1,243,776 | -1,566,305 | -3,106,477 | -933,489 |
Short-Term Debt Issued | 237,000 | 758,500 | 593,750 | 50,000 |
Long-Term Debt Issued | 892,659 | 45,000 | 211,903 | 648,356 |
Total Debt Issued | 1,129,659 | 803,500 | 805,653 | 698,356 |
Short-Term Debt Repaid | -684,500 | -686,783 | -496,988 | -30,000 |
Long-Term Debt Repaid | -878,947 | -751,967 | -496,906 | -171,734 |
Total Debt Repaid | -1,563,447 | -1,438,750 | -993,894 | -201,734 |
Net Debt Issued (Repaid) | -433,788 | -635,250 | -188,241 | 496,622 |
Issuance of Common Stock | - | - | 3,200,751 | - |
Other Financing Activities | - | 200 | -12,430 | -0 |
Financing Cash Flow | -433,788 | -635,050 | 3,000,080 | 496,622 |
Foreign Exchange Rate Adjustments | 41,593 | 12,245 | -3,242 | 831.1 |
Net Cash Flow | 23,284 | -522,882 | 843,409 | 18,560 |
Free Cash Flow | 355,682 | 671,158 | -3,792 | 48,343 |
Free Cash Flow Growth | -47.01% | - | - | -22.56% |
Free Cash Flow Margin | 7.82% | 18.17% | -0.13% | 3.08% |
Free Cash Flow Per Share | 7683.62 | 14498.68 | -83.52 | 1123.38 |
Cash Interest Paid | 62,086 | 63,486 | 33,940 | 18,594 |
Cash Income Tax Paid | 307,026 | 319,321 | 188,473 | 42,369 |
Levered Free Cash Flow | 55,875 | -446,653 | 21,978 | 62,860 |
Unlevered Free Cash Flow | 87,161 | -395,655 | 62,019 | 72,052 |
Change in Working Capital | -45,375 | 298,743 | -263,485 | -234,840 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.